PT-141 Dosage Chart
FDA-approved Vyleesi 1.75 mg as-needed protocol, timing, the 8-doses-per-month ceiling, and off-label male use.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women (2019). It is also used off-label by men. Unlike PDE5 inhibitors (sildenafil, tadalafil), PT-141 acts on melanocortin receptors in the central nervous system rather than peripheral vasculature.
PT-141 at a Glance
| FDA-labeled dose (Vyleesi) | 1.75 mg subQ as needed |
|---|---|
| Timing | At least 45 minutes before anticipated sexual activity |
| Frequency | Maximum 1 dose per 24 hours; maximum 8 doses per month |
| Route | Subcutaneous, abdomen or thigh |
| Off-label male use | Same 1.75 mg dose typical; some practitioners use 2 mg |
| FDA status | FDA-approved 2019 for HSDD in premenopausal women (Vyleesi) |
| Common form | Single-use auto-injector (Vyleesi); compounded vials |
PT-141 Reconstitution Chart
How vial size, bacteriostatic water volume, and insulin-syringe units convert for PT-141. Use this to translate a prescribed mcg or mg dose into a syringe measurement.
| Vial size | Bac water | Concentration | Dose → insulin-syringe units (U-100) |
|---|---|---|---|
| Vyleesi auto-injector | Pre-filled — no reconstitution | 1.75 mg per single-use injector |
|
| 10 mg (compounded) | 5 mL | 2 mg/mL (200 mcg per 0.1 mL) |
|
PT-141 Dosing by Use Case
Commonly cited protocols vary by what PT-141 is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| HSDD in premenopausal women (FDA-labeled) | 1.75 mg | As needed, ≥ 45 min before activity | Per FDA label: max 1 dose/24 hr, 8 doses/month | Discontinue if no improvement after 8 weeks of use. |
| Off-label male sexual health | 1.75–2 mg | As needed, ≥ 45 min before activity | Same as-needed schedule; not for daily use | Compounded use is off-label; monitor blood pressure during initial doses. |
Stacking PT-141
PT-141 can be combined with PDE5 inhibitors (sildenafil, tadalafil) under provider supervision since the mechanisms are different (central vs peripheral), but the combination amplifies blood pressure changes and should not be initiated without medical guidance.
PT-141 produces transient blood pressure elevation and cannot be used in uncontrolled hypertension or cardiovascular disease.
- •Most common side effects: nausea, flushing, injection-site reactions, headache, vomiting.
- •Transient blood pressure elevation (~6 mmHg systolic, ~3 mmHg diastolic) is expected; lasts roughly 8–12 hours per dose.
- •Contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.
- •Hyperpigmentation (gum, breast, facial skin) reported with frequent use — appears to be partly reversible on discontinuation.
- •Do not exceed 8 doses per month per FDA labeling.
- •Uncontrolled hypertension
- •Known cardiovascular disease
- •Pregnancy
- •History of severe nausea / GI sensitivity (relative contraindication)
PT-141 Dosing FAQ
FDA labeling specifies at least 45 minutes before anticipated sexual activity. Onset varies by individual; some users report effects building over 1–2 hours.
Vyleesi is FDA-approved only for premenopausal women with HSDD. Off-label use by men is widespread and uses the same 1.75 mg dose typically. Off-label use should be supervised by a clinician familiar with the cardiovascular monitoring requirements.
Reports indicate hyperpigmentation tends to fade after discontinuation, though complete reversal varies. Frequent dosing (close to or above the 8-doses-per-month ceiling) increases risk.
No. PT-141 is an as-needed medication, not a daily one. The FDA label caps use at 1 dose per 24 hours and 8 doses per month. Daily dosing offers no benefit and increases side-effect burden.
Sources
Want the full PT-141 guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for PT-141 therapy.
See PT-141 guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.